KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $117000.0.

  • Amneal Pharmaceuticals' Other Operating Expenses fell 8864.08% to $117000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 10476.76%. This contributed to the annual value of -$96.7 million for FY2024, which is 76697.94% down from last year.
  • Amneal Pharmaceuticals' Other Operating Expenses amounted to $117000.0 in Q3 2025, which was down 8864.08% from $390000.0 recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Other Operating Expenses registered a high of $13.4 million during Q4 2023, and its lowest value of -$251.9 million during Q2 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' median Other Operating Expenses value was -$699000.0 (recorded in 2024), while the average stood at -$21.7 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first crashed by 3156666.67% in 2021, then surged by 16648.25% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Other Operating Expenses (Quarter) stood at -$6.0 million in 2021, then tumbled by 234.9% to -$20.1 million in 2022, then surged by 166.48% to $13.4 million in 2023, then plummeted by 113.35% to -$1.8 million in 2024, then skyrocketed by 106.56% to $117000.0 in 2025.
  • Its Other Operating Expenses stands at $117000.0 for Q3 2025, versus $390000.0 for Q2 2025 and $5.1 million for Q1 2025.